Aigen Investment Management’s Pacific Biosciences PACB Stock Holding History

Aigen Investment Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-28,098	Closed	-$105K	–	960
2024 Q1	$105K	Buy	+28,098	New	+$165K	0.02%	609
2023 Q4	–	Sell	-34,671	Closed	-$290K	–	1006
2023 Q3	$290K	Buy	34,671 +22,134	+177%	+$253K	0.05%	536
2023 Q2	$167K	Buy	+12,537	New	+$152K	0.02%	646
2022 Q2	–	Sell	-12,218	Closed	-$111K	–	678
2022 Q1	$111K	Buy	12,218 +2,073	+20%	+$23.9K	0.02%	494
2021 Q4	$219K	Buy	+10,145	New	+$245K	0.01%	906
2021 Q1	–	Sell	-35,896	Closed	-$931K	–	820
2020 Q4	$931K	Buy	+35,896	New	+$610K	0.12%	224

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's PACB Position: Q2 2024 in Review

Aigen Investment Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 28,098 shares — an estimated $105K sold.

Aigen Investment Management first reported a position in PACB in Q4 2020 and held it in 6 quarters. The position peaked at $931K in Q4 2020. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Aigen Investment Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Aigen Investment Management sold 28,098 Pacific Biosciences shares in Q2 2024, an estimated $105K.
Aigen Investment Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 6 quarters.
Aigen Investment Management's Pacific Biosciences position peaked at $931K in Q4 2020.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Aigen Investment Management's 13F filing for Q2 2024, filed 9 Aug 2024.